📣 VC round data is live. Check it out!

Carasent Valuation Multiples

Discover Carasent's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Ever Fortune.AI, eWeLL, Kanamic Network, CE Holdings and more.

Carasent Overview

About Carasent

Carasent AB (publ) Formerly Carasent AB is in the businesses that develop entrepreneurial and e-health solutions. It delivers cloud based EHR solutions, with Webdoc as the platform, and a ecosystem of platform services, including solutions for patient communication and business intelligence. The ecosystem of solutions makes Carasent a one-stop shop for clinics and can cover all needs.


Founded

1997

HQ

Norway

Employees

165

Financials (LTM)

Revenue: $40M
EBITDA: $9M

EV

$151M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Carasent Financials

Carasent reported last 12-month revenue of $40M and EBITDA of $9M.

In the same LTM period, Carasent generated $34M in gross profit, $9M in EBITDA, and $4M in net income.

Revenue (LTM)


Carasent P&L

In the most recent fiscal year, Carasent reported revenue of $39M and EBITDA of $10M.

Carasent is profitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 27%, and net margin of 10%.

See analyst estimates for Carasent
LTMLast FY202320242025202620272028
Revenue$40M$39M$26M$30M$37M
Gross Profit$34M$31M$21M$25M$31M
Gross Margin84%80%81%85%84%
EBITDA$9M$10M$307K$2M$10M
EBITDA Margin23%27%1%6%28%
EBIT Margin5%3%(15%)(18%)3%
Net Profit$4M$4M($5M)($5M)$4M
Net Margin9%10%(19%)(15%)10%

Financial data powered by Morningstar, Inc.

Carasent Stock Performance

Carasent has current market cap of $162M, and enterprise value of $151M.

Market Cap Evolution


Carasent's stock price is $2.43.

Carasent share price decreased by 4.5% in the last 30 days, and by 24.4% in the last year.

Carasent has an EPS (earnings per share) of $0.06.

See more trading valuation data for Carasent
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$151M$162M-3.7%-4.5%-3.2%-24.4%$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Carasent Valuation Multiples

Carasent trades at 3.8x EV/Revenue multiple, and 16.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Carasent

EV / Revenue (LTM)


Carasent Financial Valuation Multiples

As of June 3, 2026, Carasent has market cap of $162M and EV of $151M.

Carasent has a P/E ratio of 44.3x.

LTMLast FY202320242025202620272028
EV/Revenue3.8x3.9x5.9x5.1x4.1x
EV/EBITDA16.5x14.6xn/m80.5x14.6x
EV/EBIT69.5x139.6x(38.2x)(28.5x)149.5x
EV/Gross Profit4.5x4.9x7.3x6.1x4.9x
P/E44.3x41.6x(33.1x)(35.8x)43.6x
EV/FCF72.1xn/m(19.5x)n/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Carasent Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Carasent Margins & Growth Rates

Carasent grew revenue by 10% and EBITDA by 1% in the last fiscal year.

In the most recent fiscal year, Carasent reported gross margin of 80%, EBITDA margin of 27%, and net margin of 10%.

See estimated margins and future growth rates for Carasent

Carasent Margins

Last FY202420252026202720282029
Gross Margin80%85%84%85%
EBITDA Margin27%6%28%25%
EBIT Margin3%(18%)3%9%
Net Margin10%(15%)10%8%
FCF Margin(0%)(2%)(0%)16%

Carasent Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%15%25%15%
Gross Profit Growth15%20%24%15%
EBITDA Growth1%513%450%1%
EBIT Growth239%34%(119%)263%
Net Profit Growth(15%)(7%)(182%)(11%)
FCF Growth(13144%)(93%)(91%)(13144%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Carasent Operational KPIs

Carasent's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Carasent's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Carasent's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Carasent
LTMLast FY202320242025202620272028
Rule of 4037%39%---
Bessemer Rule of X58%62%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue-1%1%0%1%
G&A Expenses to Revenue-6%23%20%6%
Opex to Revenue-78%96%102%81%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Carasent Competitors

Carasent competitors include Ever Fortune.AI, eWeLL, Kanamic Network, CE Holdings, Kusurinomadoguchi, Nano X Imaging, Airdoc, MTI Ltd., Fonet and Findex.

Most Carasent public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ever Fortune.AI12.2x-31.1x-
eWeLL7.4x6.8x15.2x13.9x
Kanamic Network3.6x3.4x9.8x9.5x
CE Holdings1.4x1.4x8.2x-
Kusurinomadoguchi2.4x2.1x9.0x6.7x
Nano X Imaging6.3x4.0x(1.7x)-
Airdoc1.6x1.6x(41.9x)-
MTI Ltd.0.6x0.6x2.9x3.7x

This data is available for Pro users. Sign up to see all Carasent competitors and their valuation data.

Start Free Trial

Acquisitions by Carasent

Carasent has acquired 5 companies to date.

Last acquisition by Carasent was on April 26th 2026. Carasent acquired InfoSolutions Sverige for $12M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Carasent

InfoSolutions Sverige
HPI Health Profile Institute AB
Medrave
Metodika
Description
InfoSolutions Sverige AB is a Swedish provider of services and products that manage information exchange between healthcare systems.
HPI Health Profile Institute AB is a Swedish developer of health assessment methods and software. Stockholm-based, it provides tools for wellness profiling, education programs, and research in preventive healthcare. The institute supports corporations and healthcare providers with digital platforms tracking employee health metrics.
-
Metodika is a software suite designed for healthcare practice management. It automates scheduling, task workflows, patient records, and billing processes while providing analytics for clinic performance. Targeted at medical offices, the platform connects daily operations to streamline administrative duties and support operational improvements.
HQ CountrySwedenSwedenSwedenSweden
HQ City
Stockholm
Stockholm
-
Stockholm
Deal Date26 Apr 202618 Oct 202215 Dec 202126 May 2021
Valuation$12M$3M$12M$10M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Carasent acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Carasent

When was Carasent founded?Carasent was founded in 1997.
Where is Carasent headquartered?Carasent is headquartered in Norway.
How many employees does Carasent have?As of today, Carasent has over 165 employees.
Who is the CEO of Carasent?Carasent's CEO is Daniel Ohman.
Is Carasent publicly listed?Yes, Carasent is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Carasent?Carasent trades under CARA ticker.
When did Carasent go public?Carasent went public in 2012.
Who are competitors of Carasent?Carasent main competitors include Ever Fortune.AI, eWeLL, Kanamic Network, CE Holdings, Kusurinomadoguchi, Nano X Imaging, Airdoc, MTI Ltd., Fonet, Findex.
What is the current market cap of Carasent?Carasent's current market cap is $162M.
What is the current revenue of Carasent?Carasent's last 12 months revenue is $40M.
What is the current revenue growth of Carasent?Carasent revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Carasent?Current revenue multiple of Carasent is 3.8x.
What is the current EBITDA of Carasent?Carasent's last 12 months EBITDA is $9M.
What is Carasent's EBITDA margin?Carasent's last 12 months EBITDA margin is 23%.
What is the current EV/EBITDA multiple of Carasent?Current EBITDA multiple of Carasent is 16.5x.
What is the current FCF of Carasent?Carasent's last 12 months FCF is $2M.
What is Carasent's FCF margin?Carasent's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Carasent?Current FCF multiple of Carasent is 72.1x.
How many companies Carasent has acquired to date?As of June 2026, Carasent has acquired 5 companies.
What was the largest acquisition by Carasent?$12M acquisition of InfoSolutions Sverige on 26th April 2026 was the largest M&A Carasent has done to date.
What companies Carasent acquired?Carasent acquired InfoSolutions Sverige, Avans Soma, Medrave, Metodika, and HPI Health Profile Institute AB.
In how many companies Carasent has invested to date?Carasent hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Carasent

Lists including Carasent

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial